Elevations in granulocyte-macrophage colony-stimulating factor and interleukin-5 levels precede posttreatment eosinophilia in onchocerciasis

John B. Hagan, Kathleen R. Bartemes, Hirohito Kita, Eric A. Ottesen, Kwablah Awadzi, Thomas B. Nutman, Gerald J. Gleich

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The eosinophil survival assay was used to quantitate cytokines in 17 serial serum samples from 10 patients treated for onchocerciasis with diethylcarbamazine. Eosinophils isolated from normal donors were cultured for 4 days in the presence of patients' sera, and cell viability was determined. Serum specimens from 9 of 10 patients enhanced eosinophil survival from 4.8% ± 2.2% (mean ± SE) before treatment to 50.0% ± 6.4% after treatment. Survival enhancement activity peaked before posttreatment eosinophilia. Antibodies to interleukin (IL)-5, granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-3 were used to block cytokine activity in 22 serum samples. Antibodies to IL-5 blocked survival in 5 samples, antibodies to GM- CSF blocked survival in 6 samples, and a combination of antibodies to IL-5 and GM-CSF blocked survival in 8 additional samples. Overall, posttreatment sera from patients treated for onchocerciasis enhanced eosinophil survival; both GM-CSF and IL-5 may promote the posttreatment eosinophilia in filarial infection.

Original languageEnglish (US)
Pages (from-to)1277-1280
Number of pages4
JournalJournal of Infectious Diseases
Volume173
Issue number5
StatePublished - 1996
Externally publishedYes

Fingerprint

Onchocerciasis
Interleukin-5
Eosinophilia
Granulocyte-Macrophage Colony-Stimulating Factor
Eosinophils
Serum
Survival
Antibodies
Diethylcarbamazine
Cytokines
Interleukin-3
Cell Survival
Tissue Donors
Therapeutics
Infection

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Hagan, J. B., Bartemes, K. R., Kita, H., Ottesen, E. A., Awadzi, K., Nutman, T. B., & Gleich, G. J. (1996). Elevations in granulocyte-macrophage colony-stimulating factor and interleukin-5 levels precede posttreatment eosinophilia in onchocerciasis. Journal of Infectious Diseases, 173(5), 1277-1280.

Elevations in granulocyte-macrophage colony-stimulating factor and interleukin-5 levels precede posttreatment eosinophilia in onchocerciasis. / Hagan, John B.; Bartemes, Kathleen R.; Kita, Hirohito; Ottesen, Eric A.; Awadzi, Kwablah; Nutman, Thomas B.; Gleich, Gerald J.

In: Journal of Infectious Diseases, Vol. 173, No. 5, 1996, p. 1277-1280.

Research output: Contribution to journalArticle

Hagan, John B. ; Bartemes, Kathleen R. ; Kita, Hirohito ; Ottesen, Eric A. ; Awadzi, Kwablah ; Nutman, Thomas B. ; Gleich, Gerald J. / Elevations in granulocyte-macrophage colony-stimulating factor and interleukin-5 levels precede posttreatment eosinophilia in onchocerciasis. In: Journal of Infectious Diseases. 1996 ; Vol. 173, No. 5. pp. 1277-1280.
@article{800e246611ec4456aa75260956047371,
title = "Elevations in granulocyte-macrophage colony-stimulating factor and interleukin-5 levels precede posttreatment eosinophilia in onchocerciasis",
abstract = "The eosinophil survival assay was used to quantitate cytokines in 17 serial serum samples from 10 patients treated for onchocerciasis with diethylcarbamazine. Eosinophils isolated from normal donors were cultured for 4 days in the presence of patients' sera, and cell viability was determined. Serum specimens from 9 of 10 patients enhanced eosinophil survival from 4.8{\%} ± 2.2{\%} (mean ± SE) before treatment to 50.0{\%} ± 6.4{\%} after treatment. Survival enhancement activity peaked before posttreatment eosinophilia. Antibodies to interleukin (IL)-5, granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-3 were used to block cytokine activity in 22 serum samples. Antibodies to IL-5 blocked survival in 5 samples, antibodies to GM- CSF blocked survival in 6 samples, and a combination of antibodies to IL-5 and GM-CSF blocked survival in 8 additional samples. Overall, posttreatment sera from patients treated for onchocerciasis enhanced eosinophil survival; both GM-CSF and IL-5 may promote the posttreatment eosinophilia in filarial infection.",
author = "Hagan, {John B.} and Bartemes, {Kathleen R.} and Hirohito Kita and Ottesen, {Eric A.} and Kwablah Awadzi and Nutman, {Thomas B.} and Gleich, {Gerald J.}",
year = "1996",
language = "English (US)",
volume = "173",
pages = "1277--1280",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Elevations in granulocyte-macrophage colony-stimulating factor and interleukin-5 levels precede posttreatment eosinophilia in onchocerciasis

AU - Hagan, John B.

AU - Bartemes, Kathleen R.

AU - Kita, Hirohito

AU - Ottesen, Eric A.

AU - Awadzi, Kwablah

AU - Nutman, Thomas B.

AU - Gleich, Gerald J.

PY - 1996

Y1 - 1996

N2 - The eosinophil survival assay was used to quantitate cytokines in 17 serial serum samples from 10 patients treated for onchocerciasis with diethylcarbamazine. Eosinophils isolated from normal donors were cultured for 4 days in the presence of patients' sera, and cell viability was determined. Serum specimens from 9 of 10 patients enhanced eosinophil survival from 4.8% ± 2.2% (mean ± SE) before treatment to 50.0% ± 6.4% after treatment. Survival enhancement activity peaked before posttreatment eosinophilia. Antibodies to interleukin (IL)-5, granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-3 were used to block cytokine activity in 22 serum samples. Antibodies to IL-5 blocked survival in 5 samples, antibodies to GM- CSF blocked survival in 6 samples, and a combination of antibodies to IL-5 and GM-CSF blocked survival in 8 additional samples. Overall, posttreatment sera from patients treated for onchocerciasis enhanced eosinophil survival; both GM-CSF and IL-5 may promote the posttreatment eosinophilia in filarial infection.

AB - The eosinophil survival assay was used to quantitate cytokines in 17 serial serum samples from 10 patients treated for onchocerciasis with diethylcarbamazine. Eosinophils isolated from normal donors were cultured for 4 days in the presence of patients' sera, and cell viability was determined. Serum specimens from 9 of 10 patients enhanced eosinophil survival from 4.8% ± 2.2% (mean ± SE) before treatment to 50.0% ± 6.4% after treatment. Survival enhancement activity peaked before posttreatment eosinophilia. Antibodies to interleukin (IL)-5, granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-3 were used to block cytokine activity in 22 serum samples. Antibodies to IL-5 blocked survival in 5 samples, antibodies to GM- CSF blocked survival in 6 samples, and a combination of antibodies to IL-5 and GM-CSF blocked survival in 8 additional samples. Overall, posttreatment sera from patients treated for onchocerciasis enhanced eosinophil survival; both GM-CSF and IL-5 may promote the posttreatment eosinophilia in filarial infection.

UR - http://www.scopus.com/inward/record.url?scp=0030015014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030015014&partnerID=8YFLogxK

M3 - Article

VL - 173

SP - 1277

EP - 1280

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -